Nurix Therapeutics logo

Nurix Therapeutics Share Price Today

(NASDAQ: NRIX)

Nurix Therapeutics share price is $14.27 & ₹1,241.05 as on 6 Mar 2025, 2.30 'hrs' IST

$14.27

▲

0.01

(0.07%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Nurix Therapeutics share price in Dollar and Rupees. Guide to invest in Nurix Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Nurix Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Nurix Therapeutics share price movements

  • Today's Low: $13.86
    Today's High: $14.52

    Day's Volatility :4.55%

  • 52 Weeks Low: $11.90
    52 Weeks High: $29.56

    52 Weeks Volatility :59.74%

Nurix Therapeutics (NRIX) Returns

PeriodNurix Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-28.91%
2.1%
0.0%
6 Months
-41.65%
-4.1%
0.0%
1 Year
-8.94%
2.2%
0.0%
3 Years
3.71%
11.8%
-11.6%

Nurix Therapeutics (NRIX) Key Statistics

in dollars & INR

Previous Close
$14.26
Open
$14.2
Today's High
$14.52
Today's Low
$13.86
Market Capitalization
$1.1B
Today's Volume
$178.0K
52 Week High
$29.56
52 Week Low
$11.9
Revenue TTM
$54.5M
EBITDA
$-205.0M
Earnings Per Share (EPS)
$-2.88
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-53.22%

How to invest in Nurix Therapeutics Stock (NRIX) from India?

It is very easy for Indian residents to invest directly in Nurix Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nurix Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Nurix Therapeutics or NRIX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nurix Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nurix Therapeutics shares which would translate to 0.061 fractional shares of Nurix Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Nurix Therapeutics, in just a few clicks!

Returns in Nurix Therapeutics (NRIX) for Indian investors in Rupees

The Nurix Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Nurix Therapeutics investment value today

Current value as on today

₹96,087

Returns

₹3,913

(-3.91%)

Returns from Nurix Therapeutics Stock

₹8,876 (-8.88%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Nurix Therapeutics (NRIX)

25%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Nurix Therapeutics Stock from India on INDmoney has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Nurix Therapeutics

  • FMR Inc

    14.01%

  • BlackRock Inc

    10.11%

  • Vanguard Group Inc

    5.73%

  • Redmile Group, LLC

    5.52%

  • Baker Bros Advisors LP

    5.12%

  • Wellington Management Company LLP

    4.73%

Analyst Recommendation on Nurix Therapeutics

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Nurix Therapeutics(by analysts ranked 0 to 5 stars)

Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
16
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Nurix Therapeutics Stock (NRIX)

What analysts predicted

Upside of 126.19%

Target:

$32.28

Current:

$14.27

Insights on Nurix Therapeutics Stock (Ticker Symbol: NRIX)

  • Price Movement

    In the last 7 days, NRIX stock has moved down by -16.4%

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 12.09M → 13.28M (in $), with an average increase of 4.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -41.51M → -58.54M (in $), with an average decrease of 12.3% per quarter

  • NRIX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 55.4%

  • NRIX vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 43.8%

  • Price to Sales

    ForNRIX every $1 of sales, investors are willing to pay $17.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

NRIX Nurix Therapeutics Financials in INR & Dollars

FY19Y/Y Change
Revenue
$31.1M
↓ 16.91%
Net Income
$-21.7M
↑ 130.15%
Net Profit Margin
-69.74%
↓ 44.56%
FY20Y/Y Change
Revenue
$17.8M
↓ 42.73%
Net Income
$-43.2M
↑ 99.28%
Net Profit Margin
-242.66%
↓ 172.92%
FY21Y/Y Change
Revenue
$29.8M
↑ 66.95%
Net Income
$-117.2M
↑ 171.02%
Net Profit Margin
-393.93%
↓ 151.27%
FY22Y/Y Change
Revenue
$38.6M
↑ 29.84%
Net Income
$-166.0M
↑ 41.68%
Net Profit Margin
-429.87%
↓ 35.94%
FY23Y/Y Change
Revenue
$77.0M
↑ 99.31%
Net Income
$-143.9M
↓ 13.31%
Net Profit Margin
-186.98%
↑ 242.89%
FY24Y/Y Change
Revenue
$54.5M
↓ 29.15%
Net Income
$-193.6M
↑ 34.47%
Net Profit Margin
-354.85%
↓ 167.87%
Q3 FY23Q/Q Change
Revenue
$18.5M
↓ 39.8%
Net Income
$-37.0M
↑ 69.73%
Net Profit Margin
-200.26%
↓ 129.23%
Q4 FY23Q/Q Change
Revenue
$15.2M
↓ 17.91%
Net Income
$-42.0M
↑ 13.45%
Net Profit Margin
-276.77%
↓ 76.51%
Q1 FY24Q/Q Change
Revenue
$16.6M
↑ 9.41%
Net Income
$-41.5M
↓ 1.04%
Net Profit Margin
-250.33%
↑ 26.44%
Q2 FY24Q/Q Change
Revenue
$12.1M
↓ 27.09%
Net Income
$-44.5M
↑ 7.29%
Net Profit Margin
-368.39%
↓ 118.06%
Q3 FY24Q/Q Change
Revenue
$12.6M
↑ 4.1%
Net Income
$-49.0M
↑ 9.9%
Net Profit Margin
-388.91%
↓ 20.52%
Q4 FY24Q/Q Change
Revenue
$13.3M
↑ 5.53%
Net Income
$-58.5M
↑ 19.6%
Net Profit Margin
-440.75%
↓ 51.84%
FY19Y/Y Change
Profit
$-13.9M
↓ 137.14%
FY20Y/Y Change
Profit
$17.8M
↓ 228.11%
FY21Y/Y Change
Profit
$29.8M
↑ 66.95%
FY22Y/Y Change
Profit
$38.6M
↑ 29.84%
FY23Y/Y Change
Profit
$-112.2M
↓ 390.37%
FY24Y/Y Change
Profit
$54.5M
↓ 148.63%
Q3 FY23Q/Q Change
Profit
$15.1M
↓ 44.84%
Q4 FY23Q/Q Change
Profit
$11.4M
↓ 24.4%
Q1 FY24Q/Q Change
Profit
$12.7M
↑ 11.36%
Q2 FY24Q/Q Change
Profit
$8.0M
↓ 36.99%
Q3 FY24Q/Q Change
Profit
$8.4M
↑ 5.51%
Q4 FY24Q/Q Change
Profit
$13.3M
↑ 57.36%
FY19Y/Y Change
Operating Cash Flow
$601.0K
↓ 101.9%
Investing Cash Flow
$8.5M
↓ 78.75%
Financing Cash Flow
$126.0K
↓ 76.18%
FY20Y/Y Change
Operating Cash Flow
$-80.0K
↓ 113.31%
Investing Cash Flow
$-254.4M
↓ 3093.69%
Financing Cash Flow
$339.0M
↑ 268966.67%
FY21Y/Y Change
Operating Cash Flow
$-84.4M
↑ 105356.25%
Investing Cash Flow
$-108.3M
↓ 57.45%
Financing Cash Flow
$153.9M
↓ 54.61%
FY22Y/Y Change
Operating Cash Flow
$-159.8M
↑ 89.42%
Investing Cash Flow
$27.2M
↓ 125.12%
Financing Cash Flow
$117.2M
↓ 23.84%
Q3 FY23Q/Q Change
Operating Cash Flow
$-41.1M
↑ 122.71%
Investing Cash Flow
$22.8M
↓ 48.04%
Financing Cash Flow
$1.7M
↑ 6716.0%

Nurix Therapeutics Technicals Summary

Sell

Neutral

Buy

Nurix Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Nurix Therapeutics (NRIX) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nurix Therapeutics Inc logo
Nurix Therapeutics Inc
-24.75%
-41.65%
-8.94%
3.71%
-24.99%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
Beone Medicines Ltd
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nurix Therapeutics Inc logo
Nurix Therapeutics Inc
NA
NA
NA
-3.09
-0.53
-0.26
NA
6.95
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nurix Therapeutics Inc logo
Nurix Therapeutics Inc
Buy
$1.1B
-24.99%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
Buy
$31.5B
120.93%
NA
-12.37%

About Nurix Therapeutics

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Organization
Nurix Therapeutics
Employees
286
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Industry
Health Technology

Management People of Nurix Therapeutics

NameTitle
Dr. Arthur T. Sands M.D., Ph.D.
CEO, President & Director
Mr. Johannes Van Houte
Chief Financial Officer
Dr. Gwenn M. Hansen Ph.D.
Chief Scientific Officer
Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Rita Kwong
Senior Accounting Manager
Dr. Pasit Phiasivongsa Ph.D.
Chief Technical Officer
Dr. Christine Ring J.D., Ph.D.
Chief Legal Officer, Secretary & Chief Compliance Officer
Dr. Jason Kantor Ph.D.
Chief Business Officer
Mr. Christopher B. Phelps Ph.D.
Senior VP & Head of Early Drug Discovery

Important FAQs about investing in NRIX Stock from India :

What is Nurix Therapeutics share price today?

Nurix Therapeutics share price today stands at $14.27, Open: $14.20 ; Previous Close: $14.26 ; High: $14.52 ; Low: $13.86 ; 52 Week High: $29.56 ; 52 Week Low: $11.90.

The stock opens at $14.20, after a previous close of $14.26. The stock reached a daily high of $14.52 and a low of $13.86, with a 52-week high of $29.56 and a 52-week low of $11.90.

Can Indians buy Nurix Therapeutics shares?

Yes, Indians can invest in the Nurix Therapeutics (NRIX) from India.

With INDmoney, you can buy Nurix Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Nurix Therapeutics at zero transaction cost.

How can I buy Nurix Therapeutics shares from India?

It is very easy to buy Nurix Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nurix Therapeutics (NRIX) be purchased?

Yes, you can buy fractional shares of Nurix Therapeutics with INDmoney app.

What are the documents required to start investing in Nurix Therapeutics stocks?

To start investing in Nurix Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Nurix Therapeutics Stock (NRIX)?

Today’s highest price of Nurix Therapeutics (NRIX) is $14.52.

Today’s lowest price of Nurix Therapeutics (NRIX) is $13.86.

What is today's market capitalisation of Nurix Therapeutics?

Today's market capitalisation of Nurix Therapeutics NRIX is 1.1B

What is the 52 Week High and Low Range of Nurix Therapeutics Stock (NRIX)?

  • 52 Week High

    $29.56

  • 52 Week Low

    $11.90

What are the historical returns of Nurix Therapeutics (NRIX)?

  • 1 Month Returns

    -24.75%

  • 3 Months Returns

    -41.65%

  • 1 Year Returns

    -8.94%

  • 5 Years Returns

    -24.99%

Who is the Chief Executive Officer (CEO) of Nurix Therapeutics ?

Dr. Arthur T. Sands M.D., Ph.D. is the current Chief Executive Officer (CEO) of Nurix Therapeutics.